UniQure Beats Q2 Revenue Estimates, Extends Cash Runway to 2030

UniQure NV (NASDAQ: QURE) reported second-quarter financial results that surpassed analyst revenue forecasts and announced a significantly extended cash runway following a successful capital raise. The Netherlands-based gene therapy specialist is now funded for operations into the next decade as it prepares for potential commercial launches.

Second-Quarter Performance

UniQure posted total revenues of $5.80 million for the second quarter, beating the consensus analyst estimate of $5.47 million. The company attributed the year-over-year revenue increase to higher license revenue.

Despite the revenue beat, the company's net loss widened during the period. This was driven by two main factors:

• An increase in selling, general, and administrative (SG&A) expenses due to higher costs for employees and contractors as UniQure builds out its commercial infrastructure.
• A rise in non-operating expenses, which the company said resulted from unfavorable foreign currency movements and changes in the fair value of pre-funded warrant liabilities.

Strengthened Balance Sheet

Ad

A key development for the company was the completion of a follow-on offering that raised $259 million. UniQure stated that these proceeds, combined with its existing resources, have extended its cash runway into 2030.

This strengthened financial position is critical for a development-stage biotechnology firm, providing long-term stability to advance its clinical pipeline and fund operations without the near-term need for additional financing.

Upcoming Clinical Catalysts

Investors are now looking ahead to several key milestones for UniQure's clinical programs. The company plans to submit regulatory filings for its gene therapy candidate, AMT-130, to authorities in the U.S. and the U.K. during the third quarter of 2026.

Furthermore, UniQure expects to release topline four-year data from the Phase I/II study of AMT-130 in September 2026. This data will be closely watched as a key indicator of the treatment's long-term efficacy and safety.